BioPharma Credit PLC Transfer of Shares to the Premium Segment (9592N)
October 05 2021 - 1:00AM
UK Regulatory
TIDMBPCR TIDMBPCP
RNS Number : 9592N
BioPharma Credit PLC
05 October 2021
LEI: 213800AV55PYXAS7SY24
5 October 2021
BIOPHARMA CREDIT PLC
(THE "COMPANY")
TRANSFER OF ORDINARY SHARES TO THE PREMIUM SEGMENT OF THE LONDON
STOCK EXCHANGE AND INTRODUCTION OF STERLING QUOTE
Further to its announcement on 30 September 2021, BioPharma
Credit plc (the "Company" or "BioPharma Credit") is pleased to
announce the admission of all of its ordinary shares (the "Ordinary
Shares") to listing on the Official List of the Financial Conduct
Authority and to trading on the Premium Segment of London Stock
Exchange plc's Main Market ("Admission"). The application for
Admission was approved by shareholder vote at the general meeting
held on 30 September 2021.
Admission is expected to become effective at 8:00 a.m. today.
The Company's existing ticker, ISIN and SEDOL will remain
unchanged.
The Company has applied to introduce an additional market quote
for the Ordinary Shares on the London Stock Exchange denominated in
GBP (the "GBP Quote"), in connection with which the Company will
introduce a new ticker and SEDOL with effect from 8:00 a.m. on 5
October 2021, as set out below. The GBP Quote will appear alongside
the Company's existing USD market quote (the "USD Quote") and there
will be no changes to the legal form or nature of the Company's
shares nor to the reporting currency of the Company's financial
statements or the NAV (which will remain in USD).
USD Quote GBP Quote
ISIN GB00BDGKMY29 GB00BDGKMY29
------------- -------------
SEDOL BDGKMY2 BP2NZ40
------------- -------------
Ticker BPCR LN BPCP LN
------------- -------------
For Further Information
BioPharma Credit plc
Via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 509
J.P. Morgan Cazenove
William Simmonds / Harry Randall (Corporate Finance)
+44 (0)20 7742 4000
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
Biopharmacredit@buchanan.uk.com
About BioPharma Credit plc:
BioPharma Credit PLC is London's only listed specialist investor
in debt from the life sciences industry and joined the LSE on 27
March 2017. The Company seeks to provide long-term shareholder
returns, principally in the form of sustainable income
distributions from exposure to the life sciences industry. The
Company seeks to achieve this objective primarily through
investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.
Visit the BioPharma Credit website at http://bpcruk.com for more
information.
Capitalised terms used but not defined in this announcement will
have the same meaning as set out in the circular published by the
Company on 10 September 2021 unless the context otherwise
requires.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKQBKPBDDCKK
(END) Dow Jones Newswires
October 05, 2021 02:00 ET (06:00 GMT)
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From Apr 2023 to Apr 2024